Protagonist Therapeutics Stock (NASDAQ:PTGX)
Previous Close
$46.76
52W Range
$14.78 - $48.89
50D Avg
$45.07
200D Avg
$34.53
Market Cap
$2.75B
Avg Vol (3M)
$608.28K
Beta
2.17
Div Yield
-
PTGX Company Profile
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PLRX | Pliant Therapeutics, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| ARVN | Arvinas, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| MRUS | Merus N.V. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| RNA | Avidity Biosciences, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| REPL | Replimune Group, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| KURA | Kura Oncology, Inc. |
| VRNA | Verona Pharma plc |